UNSPSC 51272307: Etoxadrol hydrochloride

This classification denotes an anesthetic agent with the molecular formula C16H23NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OB67QC801N, chemically known as piperidine, 2-(2-ethyl-2-phenyl-1,3-dioxolan-4-yl),hydrochloride but more generally known as etoxadrol hydrochloride, which bears US NIH Compound Identifier 170363. Most nations, for tariff and trade purposes, schedule etoxadrol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, ETOXADROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Etoxadrol hydrochloride bears US NLM identifiers UMLS ID C2825621 and NCI Concept Code C81412. SMILES: CC[C@@]1(OC[C@@H](O1)[C@@H]2CCCCN2)C3CCCCC3.CL.

UNSPSC 51272307 Etoxadrol hydrochloride is a Commodity code, but the recent state and local opportunities tagged under it reflect actual procurement of naloxone, generic pharmaceuticals, and pharmacy benefit management services rather than the specific chemical compound named. State and local agencies are sourcing finished pharmaceutical products—including naloxone kits, over-the-counter items, and generic multi-source drugs—through competitive bids and cooperative purchasing agreements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances, with work spanning public health delivery, pharmacy benefit administration, and drug supply chain logistics. The scope encompasses product procurement with qualified wholesaler distribution, compliance with cGMP and Drug Supply Chain Security Act standards, quarterly or annual delivery schedules, and pricing models negotiated on fixed-fee, net-price, or WAC-minus bases.

Procurement activity appears concentrated in Florida and Minnesota, with broader multistate coordination through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) reaching participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Department of Administration's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) requiring NDC-level product specifications and wholesaler relationships; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM structures. The code shows activity in pharmaceutical supply and community health procurement across state and county jurisdictions, though the mismatch between the code name (a specific hydrochloride compound) and the broader product categories actually being solicited suggests potential coding inconsistency in source records.